TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00410163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab 500mg
Description: Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab 1000mg
Description: Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
Study: NCT04158609

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler flow indices assessment
Description: Doppler flow indices, UA-PI, MCA-PI and CPR values, assessment performed prior to induction of labor

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler flow indices assessment
Description: Doppler flow indices, UA-PI, MCA-PI and CPR values, assessment performed prior to induction of labor
Study: NCT03318341

Intervention type: DEVICE
Group type: OTHER
Intervention: Real Stimulation
Description: The device applies wrist vibration at a subthreshold (imperceptible) level.

Intervention type: DEVICE
Group type: OTHER
Intervention: Real Stimulation
Description: The device applies wrist vibration at a subthreshold (imperceptible) level.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Stimulation
Description: The device applies no vibration.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Stimulation
Description: The device applies no vibration.
Study: NCT00248053

Intervention type: DRUG
Group type: OTHER
Intervention: curcumin
Description: curcumin 500 mg by mouth, three times a day for 9 months
Study: NCT00439621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP 01
Description: Active immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP 01
Description: Active immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP 01
Description: Active immunotherapy

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RP 01
Description: Active immunotherapy
Study: NCT00769418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odanacatib
Description: Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days.
Study: NCT03579667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: 12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
Study: NCT02948400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pedestrian safety training in pedestrian virtual environment
Description: pedestrian safety training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pedestrian safety training in pedestrian virtual environment
Description: pedestrian safety training
Study: NCT04068532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104
Description: Administered as specified in the treatment arm.
Study: NCT02674659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session was held for around 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
Study: NCT05799456

Intervention type: DIAGNOSTIC_TEST
Intervention: Free glycosaminoglycan profiling
Description: Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.
Study: NCT02321527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Protein-Type A Microspheres Injectable Suspension
Description: Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS)
Description: Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy + Radioactive Seed Placement
Description: Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
Study: NCT01995916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Description: The Mindfulness Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support Group
Description: The Social Support Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
Study: NCT01334099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External local radiation therapy
Description: One cycle of 2000cGy administered locally to one site over 5 days.
Study: NCT04777513

Intervention type: PROCEDURE
Intervention: CCTA (Coronary Computed Tomography Angiography)
Description: Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
Study: NCT04662515

Intervention type: DRUG
Intervention: Apixaban

Intervention type: DRUG
Intervention: Edoxaban
Study: NCT04777513

Intervention type: PROCEDURE
Intervention: ICA (Invasive Coronary Angiography)
Description: Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.

Intervention type: PROCEDURE
Intervention: FFR (Fractional Flow Reserve)
Description: Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
Study: NCT04662515

Intervention type: DRUG
Intervention: Warfarin
Study: NCT02911831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study: NCT04777513

Intervention type: DEVICE
Intervention: CNBP measurement
Description: Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.

Intervention type: DEVICE
Intervention: Cardiolens FFR-CT Pro
Description: Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
Study: NCT01658410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BQ-123
Description: BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl, Route: intracoronary
Study: NCT00808925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to heat
Description: Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
Study: NCT02964871

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sofia Fluorescent Immunoassay Analyzer Influenza A+B
Description: The Sofia Influenza A+B Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and influenza B viral nucleoprotein antigens.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Our team will discuss our interest in monitoring influenza antiviral treatment and prophylaxis courses, antibiotic courses, clinician and emergency room visits, respiratory infection-related hospitalizations, all-cause hospitalizations, and deaths during the anticipated 4-month influenza season over 3 years.
Study: NCT02841046

Intervention type: DEVICE
Group type: OTHER
Intervention: cardiac index
Description: group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke Volume Variation
Description: group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
Study: NCT02911831

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Study: NCT03966430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: damage control surgery
Description: 1. Emergency surgery stage, (a) the hybrid operating room restores mesenteric vascular patency. (b) excision of the necrotic intestine (c) retention of suspicious intestinal ducts, double stoma (d) establishment of catheter thrombolysis pathway (e) apply TAC to maintain open abdominal.~2. ICU phase, including (a) fluid resuscitation; (b) anti-infective and organ function support therapy; (c) continued local anticoagulation, thrombolysis (d) arrange planned re-laparotomy (e) early EN.~3. Definitive surgical procedures, including (a) Deterministic fascia closure or further removal of the necrotic intestine. (b) Intestinal stoma care and enteral nutrition support treatment. (c) An enterostomy was performed about 6 months after the first operation.
Study: NCT03803826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D re-programming
Description: The previously implanted, ineffective CRT-D is reprogrammed under supervision of Trans-Thoracic Echocardiography (TTE) to:~1. adjust the atrioventricular interval so that E and A waves do not overlap~2. the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trans-Thoracic Echocardiography
Description: This intervention relates to the determination of strains and atrioventricular interval and supplies data for reprogramming the ineffective CRT-D~Transthoracic echocardiography performed to determine the left ventricular ejection fraction as an outcome measure is not considered intervention here (as it is also performed in the control group and that would cause an error cross-referencing.
Study: NCT03966430

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non-damage control surgery
Description: The patients are diagnosed with AMI and treated for mesenteric thrombosis and ischemic bowel.~1. The patient retains the endoluminal catheter after the DSA was diagnosed as AMI.~2. After diagnosis, the operation is performed in the general operating room, and the intestinal fistula double or the anastomosis is performed according to the judgment of the surgeon.~3. After the operation, re-laparotomy is performed on demand.
Study: NCT00809198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose sodium
Study: NCT03769493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile After-Care Support (MACS) app
Description: The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
Study: NCT02383615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous nerve block
Description: Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous nerve block
Description: Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
Study: NCT00049569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study: NCT02954172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab in Combination With Paclitaxel/Carboplatin
Description: Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
Study: NCT00049569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM
Study: NCT02954172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBI305 in Combination with Paclitaxel/Carboplatin
Description: Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
Study: NCT00275548

Intervention type: DRUG
Group type: OTHER
Intervention: Pegasys
Description: 135-180 micrograms administered sc once weekly

Intervention type: DRUG
Group type: OTHER
Intervention: Pegasys
Description: 135-180 micrograms administered sc once weekly

Intervention type: DRUG
Group type: OTHER
Intervention: Copegus
Description: 400-1200 mg/day for 48 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Copegus
Description: 400-1200 mg/day for 48 weeks
Study: NCT01032109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
Study: NCT00049569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT02657785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-IDARAM plus intrathecal chemotherapy
Description: R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
Study: NCT03882268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIYCN interventions
Description: 1. Capacity building for health providers and nutrition counselors (training on MIYCN SBCC from A\&T).~2. Dedicated room for MIYCN counseling at health facilities with standardized layouts, displays of government IYCF logo, and other specifications.~3. Availability of standardized MIYCN-specific BCC materials and job aids.~4. Standardized MIYCN counseling services (counseling on diet diversity and quantity, IFA and calcium supplementation, weight gain monitoring, exclusive and early initiation of breastfeeding, complementary feeding, and water, sanitation and health) provided by a dedicated MIYCN counselor hired by A\&T.~5. Dedicated community worker hired by A\&T to identify and mobilize beneficiaries needing services in the community (via satellite clinic outreach, distribute MIYCN flyers, and provision of MIYCN education via phone or home visits).~6. Supportive supervision of MIYCN counselors and community workers by program and facility managers, and field supervisors.
Study: NCT02978599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVL-3288
Description: daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVL-3288
Description: daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily for 5 days
Study: NCT02562664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: 100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
Study: NCT00049569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study: NCT02562664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: 100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets taken twice daily continuously for three cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
Study: NCT02659397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
Study: NCT02228980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
Description: 0.25 mL Intramuscular (2 doses given 28 days apart)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
Description: 0.5 mL Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
Description: 0.5 mL Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
Description: 0.5 mL Intramuscular
Study: NCT00049569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT02948517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Time restricted feeding